

IN THE CLAIMS:

Please cancel Claims 3, 8-17, 20 and 21.

follows:

Sub D'

1. (Amended) An isolated DNA [related to IgA nephronpathy] comprising a nucleotide sequence selected from the group of nucleotide sequences [represented by] consisting of SEQ ID NO:1-6 and 9-12 [to NO:32 and SEQ ID NO:39 to NO:42], or

a DNA which hybridizes with said DNA [under stringent conditions] at 65°C in the presence of 0.7-1.0M NaCl using a filter on which said DNA is immobilized followed by washing the filter with 0.1 x to 2 x SSC solution (where 1 x SSC is 150 mM sodium chloride and 15 mM sodium citrate) at 65°C.

Sub B'

2. (Amended) An isolated DNA comprising a nucleotide sequence identical to any continuous 5 to 60 residues in a nucleotide sequence selected from the nucleotide sequences [represented by] consisting of the 1st to the 1894th nucleotide of SEQ ID NO:1 [to NO:32 and SEQ ID NO:39 to NO: 42], the 1st to the 2644th nucleotide of SEQ ID

A 1

NO:2, the 116th to the 2981st nucleotide of SEQ ID NO: 3, the
1st to the 1415th nucleotide of SEQ ID NO:4, the 1st to the
2666th nucleotide of SEQ ID NO:5, the 1st to the 2244th
nucleotide of SEQ ID NO:6, the 31st to the 135th nucleotide of
SEQ ID NO:9, the 1st to the 93rd nucleotide of SEQ ID NO:10,
the 48th to the 137th nucleotide of SEQ ID NO:11, and the 1st
to the 193rd nucleotide of SEQ ID NO:12, or
a DNA comprising a sequence complementary to
said DNA.

Sub D²

4. (Amended) A method for detecting mRNA [of an
IgA nephropathy-related gene] using the DNA according to any
one of claims 1 [to 3] or 2.

A 2

5. (Amended) An IgA nephropathy diagnostic agent
comprising the DNA according to any one of claims 1 [to 3] or

6. (Amended) A method for inhibiting transcription
of a[n IgA nephropathy-related] gene or translation of mRNA
of a[n IgA nephropathy-related] gene using the DNA according
to claim 2 [or 3].

a *Sub B²*
7. (Amended) A[n] method of treating IgA
nephropathy [therapeutic agent] comprising administering the
[DNA] composition according to claim [2 or 3] 19.

Sub D³
18. (Amended) A composition comprising the DNA
according to any one of claims 1 [to 3] or 2 and a diagnostic
acceptable carrier.

a³
19. (Amended) A composition comprising the DNA
according to claim 2 [or 3] and a pharmaceutical acceptable
carrier.

REMARKS

Claims 1 and 2 have been amended in order to recite the present invention with the specificity required by statute. Additionally, Claims 4-7, 18 and 19 have been amended for better conformity with accepted U.S. practice and/or to better depend from their antecedent claims. The subject matter of the amendment may be found in the specification as filed, *inter alia*, at page 7, lines 1-5. Accordingly, no new matter has been added.

The Examiner has required that Applicants affirm their provisional Election and Selection of Species. By the